Stock ENOV ENOVIS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Enovis Corporation

Equities

ENOV

US1940145022

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
55.26 USD +0.29% Intraday chart for Enovis Corporation -1.02% -1.36%
Apr. 09 Transcript : Enovis Corporation Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-09-2024 03:45 PM
Feb. 23 Canaccord Genuity Ups Price Target on Enovis to $75 From $73, Maintains Buy Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4,284 4,530 7,115 2,898 3,058 3,030 - -
Enterprise Value (EV) 1 6,486 6,664 8,483 2,898 3,293 4,085 4,066 4,017
P/E ratio -9.35 x 123 x 99.9 x -214 x -91.8 x 50.7 x 35.1 x 23.9 x
Yield - - - - - - - -
Capitalization / Revenue 1.29 x 1.48 x 1.85 x 1.85 x 1.79 x 1.43 x 1.33 x 1.23 x
EV / Revenue 1.95 x 2.17 x 2.2 x 1.85 x 1.93 x 1.93 x 1.79 x 1.63 x
EV / EBITDA 12.8 x 14.4 x 13.6 x 12.3 x 12.2 x 11 x 9.72 x 8.74 x
EV / FCF 1,170 x 35.6 x 33.7 x -18 x 258 x 91.4 x 27.9 x 10.2 x
FCF Yield 0.09% 2.81% 2.97% -5.57% 0.39% 1.09% 3.58% 9.84%
Price to Book 1.25 x 1.28 x 1.56 x - 0.89 x 0.91 x 0.92 x 0.92 x
Nbr of stocks (in thousands) 39,252 39,486 51,594 54,150 54,594 54,840 - -
Reference price 2 109.1 114.7 137.9 53.52 56.02 55.26 55.26 55.26
Announcement Date 2/21/20 2/18/21 2/22/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,327 3,071 3,854 1,563 1,707 2,118 2,278 2,458
EBITDA 1 504.9 463.2 623.1 236.1 269.2 372.9 418.1 459.9
EBIT 1 268.9 217 360.1 159.4 185.6 257.2 290.2 327.1
Operating Margin 8.08% 7.07% 9.34% 10.2% 10.87% 12.14% 12.74% 13.31%
Earnings before Tax (EBT) 1 50.49 58.03 165.4 -2.069 -67.13 3.976 33.95 -16.15
Net income 1 -527.6 42.62 71.66 -13.29 -33.26 23.42 48.53 46.63
Net margin -15.86% 1.39% 1.86% -0.85% -1.95% 1.11% 2.13% 1.9%
EPS 2 -11.67 0.9300 1.380 -0.2500 -0.6100 1.090 1.574 2.310
Free Cash Flow 1 5.546 187.2 251.9 -161.3 12.76 44.71 145.7 395.3
FCF margin 0.17% 6.09% 6.53% -10.32% 0.75% 2.11% 6.4% 16.08%
FCF Conversion (EBITDA) 1.1% 40.4% 40.42% - 4.74% 11.99% 34.86% 85.96%
FCF Conversion (Net income) - 439.06% 351.48% - - 190.96% 300.31% 847.68%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/21/20 2/18/21 2/22/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 965.9 1,023 375.5 395.1 383.8 408.7 406.2 428.5 417.5 455 505.6 533.3 516.2 563.6 547.6
EBITDA 1 159.2 156.7 47.7 56.2 57.21 74.9 56.4 65.7 65.4 81.7 80.24 93.33 90.76 108.6 87.82
EBIT 1 90.29 91.4 29.1 36.7 39.05 54.3 36.4 44.9 43.9 60.3 52.8 64.18 61.39 78.9 58.53
Operating Margin 9.35% 8.93% 7.75% 9.29% 10.17% 13.29% 8.96% 10.48% 10.51% 13.25% 10.44% 12.03% 11.89% 14% 10.69%
Earnings before Tax (EBT) 1 50.45 39.82 -46.2 116.4 -78.28 -2.54 -29.96 -19.32 -25.5 7.657 -9.988 0.766 -2.604 15.78 -4.2
Net income 1 25.85 -1.907 -39.4 76.86 -66.61 -38.6 -23.35 -9.995 -2.88 2.964 -2.786 5.643 3.296 17.26 -3.3
Net margin 2.68% -0.19% -10.49% 19.45% -17.36% -9.45% -5.75% -2.33% -0.69% 0.65% -0.55% 1.06% 0.64% 3.06% -0.6%
EPS 2 0.4800 -0.0300 -0.7243 1.410 -1.230 -0.7100 -0.4300 -0.1800 -0.0500 0.0500 0.1080 0.2700 0.2280 0.4860 0.2300
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/22/22 5/10/22 8/4/22 11/2/22 2/23/23 5/4/23 8/3/23 11/7/23 2/22/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,202 2,134 1,368 - 235 1,054 1,035 987
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 4.361 x 4.607 x 2.195 x - 0.8729 x 2.827 x 2.476 x 2.146 x
Free Cash Flow 1 5.55 187 252 -161 12.8 44.7 146 395
ROE (net income / shareholders' equity) 8.12% 5.55% 8.14% 3.07% 3.85% 4.38% 5.31% 6.31%
ROA (Net income/ Total Assets) -7.54% 0.58% 4.19% 1.93% - - - -
Assets 1 7,001 7,369 1,711 -687.1 - - - -
Book Value Per Share 2 87.50 89.70 88.70 - 62.60 60.60 60.30 60.10
Cash Flow per Share 2.870 6.520 6.870 - - - - -
Capex 1 125 115 104 105 122 150 142 148
Capex / Sales 3.77% 3.74% 2.7% 6.75% 7.16% 7.08% 6.25% 6.03%
Announcement Date 2/21/20 2/18/21 2/22/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Enovis Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
55.26 USD
Average target price
75.2 USD
Spread / Average Target
+36.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

1st Jan change Capi.
ENOVIS CORPORATION Stock Enovis Corporation
-1.36% 3.03B
STRYKER CORPORATION Stock Stryker Corporation
+12.07% 128B
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-9.04% 10.65B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
+0.91% 8.82B
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
+16.72% 7.19B
GLAUKOS CORPORATION Stock Glaukos Corporation
+25.15% 4.99B
AXONICS, INC. Stock Axonics, Inc.
+7.17% 3.4B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-8.73% 2.14B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-10.15% 2B
DOUBLE MEDICAL TECHNOLOGY INC. Stock Double Medical Technology Inc.
-22.81% 1.79B
Medical Devices & Implants
  1. Stock Market
  2. Equities
  3. ENOV Stock
  4. Financials Enovis Corporation